Company Overview


Novadip is transforming the lives of patients using its unique tissue regeneration technology platform.

The company’s highly experienced management team has a deep knowledge of science, regulation and development pathways as well a proven track record in significant fundraising for regenerative medicine companies.

Founded in 2013, based on the scientific discoveries of Dr. Denis Dufrane , Novadip is a spin-off company from the University of Louvain (UCL) and St. Luc University Hospital. The creation of Novadip  was supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II.

Using our proprietary scaffold-free, 3-dimensional technology platform for tissue regeneration to develop multiple product classes, Novadip’s mission is to provide innovative solutions for patients with limited or no effective treatment options.





Our History

2007       Reflection begins on the best stem cells for large bone defect reconstruction.

2008       Innovative 3-dimensional osteogenic structure is developed in the tissue bank at Cliniques universitaires Saint-Luc.

2009       Bone reconstruction is demonstrated in pre-clinical studies.

2010       Patent WO2010/139792 is granted for a “multi-dimensional biomaterial” and its production method. (Inventors: D. Dufrane & C. Delloye).

2010       First clinical application of the biological dressing for skin reconstruction in a chronic wound after radionecrosis is demonstrated.

2010       First clinical cases with bone regeneration therapy, in the hospital exemption setting, as a salvage therapy for bone tumour and non-union indications, show positive safety and efficacy outcomes.

2011       The selection of  adipose stem cells as the best candidate for bone reconstruction is published in Biomaterials Journal.

2012       New clinical cases with for lumbar spine and degenerative disc disease indications also demonstrate positive safety and efficacy outcomes.

2013       Preclinical results are published in Biomaterials, a leading international journal covering the science and clinical application of biomaterials.

2013       Novadip Biosciences is set-up, with a capital increase of EUR 500.000.

2013       Novadip receives grants of EUR 550.000 in non-dilutive funding from the Walloon Region.

2015       Novadip closes a EUR 28 million Series A financing round with US and Belgian investors.

2015       Novadip is granted additional EUR 4.5 million in non-dilutive funding by the Walloon Region.

2015       The development of the concept of the biological dressing for skin reconstruction   is published in the American Journal of Plastic Surgery.

2015       The clinical results of skin regeneration therapy regarding safety and efficacy, are published in: Human Adipose-Derived Mesenchymal Stem Cells in Cell Therapy: Safety and Feasibility in Different «Hospital Exemption» Clinical Applications. Vériter S, André W, Aouassar N, Poirel HA, Lafosse A, Docquier PL, Dufrane D. PLoS One. 2015 Oct 20;10(10):e0139566

2016       Novadip develops and publishes a tool to discriminate adipose stem cells to fibroblasts. Lafosse A, Dufrane D. (2016) A simple method to determine the purity human adipose-derived stem cells-based cell therapies. Stem Cell Trans Med. 2016 (in press)

2017       Novadip initiates first clinical trial testing first product candidate for bone regeneration in patients requiring single-level spinal fusion

2018       Novadip initiates first clinical trial testing second product candidate for bone regeneration in patients with large bone non-union fractures

2018       Novadip moves into its new facility with in-house GMP Class A/B cleanrooms for production of clinical batches